VOGLIZOME M0.3

Composition:

• Active Ingredients:

  • Voglibose: 0.3 mg

  • Metformin Hydrochloride: 1000 mg

Formulation:

• Form: Tablet

• Dosage Strengths:

  • Voglibose 0.3 mg + Metformin Hydrochloride 1000 mg

• Route of Administration: Oral

Status:

• Prescription Status: Prescription-only medication (Rx)

• Regulatory Approval: Approved by drug regulatory authorities (such as the FDA or equivalent) for the management of type 2 diabetes mellitus.

Benefits:

• Enhanced Glycemic Control:

  • Voglibose: An alpha-glucosidase inhibitor that helps reduce postprandial (after meal) glucose spikes by slowing the digestion and absorption of carbohydrates in the intestines.

  • Metformin Hydrochloride: A biguanide that decreases hepatic glucose production, enhances insulin sensitivity, and increases peripheral glucose uptake. The extended dose provides comprehensive glucose control.

• Dual Action: The combination of Voglibose and Metformin provides a multi-faceted approach to blood sugar management, addressing both fasting and postprandial glucose levels.

• Improved Postprandial Glucose Management: Helps in controlling spikes in blood glucose levels after meals, which can be particularly useful for patients with significant postprandial hyperglycemia.

• Complementary Therapy: This combination can be used alongside other antidiabetic medications to achieve better control of blood glucose levels and manage type 2 diabetes more effectively.